Organization | Prof. Dr. I. Chiricuta Institute of Oncology

Prof. Dr. I. Chiricuta Institute of Oncology Report issue

Academic/Hospital Phase 1 Phase 2

Organization Overview

First Clinical Trial

2008

NCT00718692

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2018

Timeline

NOW

Alternative names

Prof Dr. I Chiricuta Cluj Napoca Oncology Institute - Breast Cancer Center, Cluj Napoca, Romania | Prof. Dr. I. Chiricuta Institute of Oncology | Prof. Dr. Ion Chiricuta Oncology Institute, Cluj-Napoca, Romania

Active Ingredients

Drugs in Phase 2 Trials (9)

acetaminophen (tylenol) (1 trial)

atropine (1 trial)

bevacizumab (avastin) (1 trial)

capecitabine (xeloda) (1 trial)

lidocaine (xylocaine) (3 trials)

neostigmine (bloxiverz) (1 trial)

sevoflurane (ultane) (3 trials)

symphoglobulin-d (1 trial)

tramadol (Ultram) (1 trial)

Drugs in Phase 1 Trials (2)

fentanyl (Innovar) (1 trial)

propofol (diprivan) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Breast Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 1)

Purpura (Phase 2)

Purpura, Thrombocytopenic (Phase 2)

Purpura, Thrombocytopenic, Idiopathic (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 5
# of Trial APIs: 11